The identification of lead compounds typically involves high-throughput screening (HTS) of large chemical libraries against a specific biological target relevant to cancer. These targets could be proteins, enzymes, or pathways known to play a role in cancer progression. Promising hits from HTS undergo further validation to confirm their activity and suitability for development.
